Pulmatrix makes Robert Clarke CEO
This article was originally published in Scrip
Clinical stage biotech company Pulmatrix, which is discovering and developing a new class of therapies for respiratory diseases, has appointed Dr Robert Clarke CEO and a member of the board. Mr Clarke was previously chief scientific officer at the company, and succeeds Robert Connelly who left the company to lead a start-up company applying novel science. Mr Connelly will continue to serve on Pulmatrix's board of directors.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.